Elsevier

Life Sciences

Volume 64, Issue 19, 2 April 1999, Pages 1761-1771
Life Sciences

The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia

https://doi.org/10.1016/S0024-3205(99)00114-9Get rights and content

Abstract

Clinical studies of cholinergic pharmacotherapy, together with the putative role of the muscarinic receptor system in the neurophysiology of human behavior, support a possible muscarinic cholinergic involvement in schizophrenia. The present study has measured the density of [3H]AF-DX 384 labelled receptors (muscarinic M2 and M4) in the caudate-putamen, obtained at autopsy, from 19 subjects who had schizophrenia, and 20 subjects who did not have schizophrenia. [3H]AF-DX 384 binding was reduced in caudate-putamen from schizophrenic subjects (104 ± 10.3 νs 145 ± 901 fmol mg−1 TE; mean ± s.e.; p = 0.007). Preliminary analysis of patient drug data as well as rat studies suggest that the reduced [3H]AF-DX 384 binding in caudate-putamen of schizophrenic subjects is not wholly due to antipsychotic drug treatment, or anticholinergic medication for the treatment of extrapyramidal effects. These data suggest that the muscarinic cholinergic system may be involved in the pathology of schizophrenia.

References (39)

  • R. Tandon et al.

    Schizoph. Res.

    (1991)
  • R. Neeper et al.

    Neuropharmacol.

    (1991)
  • R. Tandon et al.

    Psychiatry Res.

    (1990)
  • V. O'Keane et al.

    Biol. Psychiatry.

    (1994)
  • C. Bolden et al.

    Europ. J. Pharmacol.

    (1991)
  • D.G. Spencer et al.

    Brain Res.

    (1986)
  • I. Aubert et al.

    Euro. J. Pharmacol.

    (1992)
  • M.R. Brann et al.

    FEBS Lett.

    (1988)
  • A. Imperato et al.

    Euro. J. Pharmacol.

    (1994)
  • J. Lehmann et al.

    Neuroscience

    (1983)
  • S. Watanabe et al.

    Life Science.

    (1983)
  • L. Jin-Long et al.

    Science In China

    (1993)
  • U. Grimm et al.

    Pharmazie.

    (1994)
  • S.H. Zorn et al.

    Eur. J. Pharmacol.

    (1994)
  • H.S. Snyder et al.

    J. Psychiat. Res.

    (1974)
  • H.S. Snyder et al.

    Arch. Gen. Psychiatry.

    (1974)
  • L.A. Baker et al.

    Br. J. Psychiatry.

    (1983)
  • B. Dean et al.

    Molec. Psychiatry.

    (1996)
  • S.H. Zom et al.

    Eur. J. Pharmacol.

    (1994)
  • Cited by (0)

    Dr Jeremy M. Crook: The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria, 3052, Australia. telephone: (03) 93881633; fax: (03) 93875061.

    View full text